Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. Beck, C. R., McKenzie, B. C., Hashim, A. B., Harris, R. C., University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group,, & Nguyen-Van-Tam, J. S. The Journal of Infectious Diseases, 206(8):1250--1259, October, 2012.
doi  abstract   bibtex   
Many national guidelines recommend annual influenza vaccination of immunocompromised patients, although the decision to vaccinate is usually at clinical discretion. We conducted a systematic review and meta-analyses to assess the evidence for influenza vaccination in this group, and we report our results by etiology. Meta-analyses showed significantly lower odds of influenza-like illness after vaccination in patients with human immunodeficiency virus (HIV) infection, patients with cancer, and transplant recipients and of laboratory-confirmed influenza in HIV-positive patients, compared with patients receiving placebo or no vaccination. Pooled odds of seroconversion and seroprotection were typically lower in HIV-positive patients, patients with cancer, and transplant recipients, compared with immunocompetent controls. Vaccination was generally well tolerated, with variation in mild adverse events between etiological groups. Limited evidence of a transient increase in viremia and a decrease in the percentage of CD4(+) cells in HIV-positive patients was found although not accompanied by worsening of clinical symptoms. Clinical judgment remains important when discussing the benefits and safety profile with immunocompromised patients.
@article{ beck_influenza_2012,
  title = {Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology},
  volume = {206},
  issn = {1537-6613},
  shorttitle = {Influenza vaccination for immunocompromised patients},
  doi = {10.1093/infdis/jis487},
  abstract = {Many national guidelines recommend annual influenza vaccination of immunocompromised patients, although the decision to vaccinate is usually at clinical discretion. We conducted a systematic review and meta-analyses to assess the evidence for influenza vaccination in this group, and we report our results by etiology. Meta-analyses showed significantly lower odds of influenza-like illness after vaccination in patients with human immunodeficiency virus (HIV) infection, patients with cancer, and transplant recipients and of laboratory-confirmed influenza in HIV-positive patients, compared with patients receiving placebo or no vaccination. Pooled odds of seroconversion and seroprotection were typically lower in HIV-positive patients, patients with cancer, and transplant recipients, compared with immunocompetent controls. Vaccination was generally well tolerated, with variation in mild adverse events between etiological groups. Limited evidence of a transient increase in viremia and a decrease in the percentage of CD4(+) cells in HIV-positive patients was found although not accompanied by worsening of clinical symptoms. Clinical judgment remains important when discussing the benefits and safety profile with immunocompromised patients.},
  language = {eng},
  number = {8},
  journal = {The Journal of Infectious Diseases},
  author = {Beck, Charles R. and McKenzie, Bruce C. and Hashim, Ahmed B. and Harris, Rebecca C. and {University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group,} and Nguyen-Van-Tam, Jonathan S.},
  month = {October},
  year = {2012},
  pmid = {22904335},
  keywords = {Drug-Related Side Effects and Adverse Reactions, HIV Infections, Humans, Immunocompromised Host, Influenza Vaccines, Influenza, Human, Neoplasms, Transplantation, Vaccination},
  pages = {1250--1259}
}

Downloads: 0